促健颗粒治疗缺血性中风恢复期（痰瘀阻络证）的临床观察

发布时间：2018-08-29 09:27

【摘要】：目的:本试验通过对主要疗效指标及次要疗效指标的观察及分析,采用国际公认的诊断标准,疗效评定标准,论证本课题促健颗粒治疗CIS(痰瘀阻络证)的临床疗效。方法:本课题从长春中医药大学附属医院脑病疗区住院的病人中收治缺血性中风恢复期(痰瘀阻络证)的患者,将符合纳入标准的60例患者随机分为试验组、对照组各30例,两组患者都进行基础治疗,口服阿司匹林肠溶片,100mg,每日一次,试验组在此基础上加服促健颗粒,每日两次,每次1份,疗程8周加6个月随访,通过主要疗效指标,发病180天时改良Rankin量表确定mRS≤2分的百分比及次要疗效指标Barthel指数,BI≥75分的比例、NIHSS量表及中医证候疗效判断标准观察对比两组的疗效差异,以论证促健颗粒的疗效。结果:经过临床观察及统计学分析,两组患者从性别、年龄、病程上没有统计学差异,两组患者均具有临床试验可比性(P0.05);经治疗8周后两组患者在改良Ra nkin量表评分、NIHSS评分、ADL评分及中医证候学评分上没有显著差异(P0.05),但是两组在第6个月随访时试验组在改良Rankin量表上≤2分的比例高于对照组,试验组在BI≥75的比例明显高于对照组,试验组在6个月随访时NIHSS评分、中医证候学评分均优于对照组(P0.05)。结论:促健颗粒治疗缺血性中风恢复期(痰瘀阻络证)临床疗效显著,效果优于单纯口服阿司匹林肠溶片,不仅能提高患者的生活能力且能降低患者的致残率。
[Abstract]:Objective: through the observation and analysis of the main curative effect index and the secondary curative effect index, using the internationally accepted diagnostic standard and the curative effect evaluation standard, the clinical curative effect of the treatment of CIS (phlegm stasis obstruction collateral syndrome) by the Caijian granule was proved. Methods: 60 patients with ischemic apoplexy (phlegm and blood stasis syndrome) were randomly divided into experimental group (control group) and control group (30 cases each) from the patients in the encephalopathy treatment area of the affiliated Hospital of Changchun University of traditional Chinese Medicine (Changchun University of traditional Chinese Medicine). The patients in both groups were treated with basic treatment, oral aspirin enteric-coated tablets 100 mg, once a day. On this basis, the experimental group took Caijian granules twice a day, once a time, the course of treatment was 8 weeks and 6 months follow-up, through the main curative effect index, The percentage of mRS 鈮，

本文编号：2210790